Arcticzymes Technologies ASA - Asset Resilience Ratio
Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 21.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Arcticzymes Technologies ASA (AZT) total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. See Arcticzymes Technologies ASA (AZT) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AZT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr76.94 Million | 21.29% |
| Total Liquid Assets | Nkr76.94 Million | 21.29% |
Asset Resilience Insights
- Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 21.29% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio
Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.29% | Nkr76.94 Million ≈ $8.10 Million |
Nkr361.41 Million ≈ $38.03 Million |
-49.57pp |
| 2024-12-31 | 70.86% | Nkr243.94 Million ≈ $25.67 Million |
Nkr344.26 Million ≈ $36.23 Million |
+17.55pp |
| 2023-12-31 | 53.31% | Nkr180.89 Million ≈ $19.04 Million |
Nkr339.32 Million ≈ $35.71 Million |
-23.22pp |
| 2022-12-31 | 76.53% | Nkr244.16 Million ≈ $25.69 Million |
Nkr319.04 Million ≈ $33.57 Million |
+5.99pp |
| 2021-12-31 | 70.54% | Nkr200.42 Million ≈ $21.09 Million |
Nkr284.11 Million ≈ $29.90 Million |
+7.38pp |
| 2020-12-31 | 63.17% | Nkr140.18 Million ≈ $14.75 Million |
Nkr221.91 Million ≈ $23.35 Million |
+22.85pp |
| 2019-12-31 | 40.32% | Nkr31.29 Million ≈ $3.29 Million |
Nkr77.61 Million ≈ $8.17 Million |
-6.24pp |
| 2018-12-31 | 46.55% | Nkr31.66 Million ≈ $3.33 Million |
Nkr68.02 Million ≈ $7.16 Million |
-3.05pp |
| 2017-12-31 | 49.60% | Nkr30.59 Million ≈ $3.22 Million |
Nkr61.68 Million ≈ $6.49 Million |
-17.60pp |
| 2016-12-31 | 67.19% | Nkr57.67 Million ≈ $6.07 Million |
Nkr85.83 Million ≈ $9.03 Million |
-- |
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more